MAPK1 and neoplasm: Additionally, there were limited data for the changes from baseline of pharmacodynamic markers in tumor tissue (e.g., phospho-ERK, phospho-AKT, and DUSP6); therefore, these data are not reported, and no definitive conclusions can be made.